Journal
CURRENT OPINION IN NEUROLOGY
Volume 30, Issue 6, Pages 589-598Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WCO.0000000000000502
Keywords
Alzheimer's disease; frontotemporal lobar degeneration; neurodegeneration; progressive supranuclear palsy; tau proteins
Categories
Funding
- CoEN
- France Alzheimer/Fondation de France
- FHU VasCog research network (Lille, France)
- programs d'investissements d'avenir LabEx (excellence laboratory) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease)
- ANR (ADORATAU)
- ANR (SPREADTAU)
- ANR (GRAND)
- Fondation pour la Recherche Medicale
- LECMA/Alzheimer Forschung Initiative
- Fondation Plan Alzheimer
- Inserm
- CNRS
- Universite Lille 2
- Lille Metropole Communaute Urbaine
- Region Nord/Pas-de-Calais
- FEDER
- DN2M
- FUI MEDIALZ
- Centre of Excellence in Neuro-degeneration (CoEN - European grant program)
- National Research Agency (ANR, France)
- program investment for the future LABEX [excellence laboratory, France - DIS-TALZ (Development of Innovative Strategies for a Trans-disciplinary approach to Alzheimer disease)]
Ask authors/readers for more resources
Purpose of review The purpose of this review is to provide an update on the role of tau beyond the stabilization of microtubules and on the clinical, pathological, diagnostic and therapeutic aspects of tauopathies. Recent findings Beyond its function as a microtubule-associated tau protein, tau is also involved in gene regulation, signal transduction and metabolism. Experimental models allow for the development of new diagnostic and therapeutic tools. Tauopathies encompass different disorders that may manifest with various clinical syndromes. Differential diagnosis with other proteinopathies is still challenging. Cerebrospinal fluid biomarkers and radiotracers were extensively studied in the last year. Although diagnostic accuracy remains deceiving in non-Alzheimer's disease tauopathies, positron emission tomography tau tracers could be used to monitor disease progression. Summary Despite the advent of novel therapeutic approaches and the increasing number of clinical trials in tauopathies, accurate clinical diagnosis is still an unmet need and better tau biomarkers are still desperately needed. Although primary taupathies are rare and heterogeneous disorders, their combined prevalence and the importance of tau disorder in Alzheimer's disease and secondary tauopathies makes research on tauopathy a priority - because it could benefit many patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available